| Title |
Long-term outcomes in patients younger than 60 years of age treated with brachytherapy for prostate cancer
|
|---|---|
| Published in |
Strahlentherapie und Onkologie, November 2017
|
| DOI | 10.1007/s00066-017-1238-2 |
| Pubmed ID | |
| Authors |
Pedro J. Prada, Juan Cardenal, Ana García Blanco, Javier Anchuelo, María Ferri, Ivan Diaz de Cerio, Andrés Vázquez, Maite Pacheco, Samuel Ruiz Arrebola |
| Abstract |
The purpose of the study was to report the outcomes and late toxicities in patients younger than 60 years of age with long-term follow-up treated with low dose rate (LDR) brachytherapy for localized prostate cancer. Between January 2000 and December 2009, 270 consecutive patients were treated with favourable localized prostate cancer; the median follow-up was 111 months (range 21-206). All patients received one implant of LDR brachytherapy. Toxicity was reported according to the Common Toxicity Criteria for Adverse Events, Version 4.0 (CTAE v4.02) by the National Cancer Institute. The overall survival according to Kaplan-Meier estimates was 99 (±1%) at 17 years. The 17-year rate for failure in tumour-free survival (TFS) was 97% (±1%), whereas for biochemical control it was 95% (±1%) at 17 years, 97% (±1%) of patients being free of local recurrence. No intraoperative or perioperative complications occurred. Acute genitourinary (GU) grade II toxicity was 4% at 12 months. No other chronic toxicity was observed after treatment. At 6 months, 94% of patients reported no change in bowel function. LDR brachytherapy provides patients younger than 60 years of age with low and intermediate-risk prostate cancer excellent outcomes and has a low risk of significant long-term GU or gastrointestinal morbidity. |
X Demographics
The data shown below were collected from the profiles of 18 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 8 | 44% |
| Colombia | 1 | 6% |
| Mexico | 1 | 6% |
| United Kingdom | 1 | 6% |
| United States | 1 | 6% |
| Korea, Democratic People's Republic of | 1 | 6% |
| Unknown | 5 | 28% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 17 | 94% |
| Scientists | 1 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 12 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 2 | 17% |
| Other | 1 | 8% |
| Lecturer | 1 | 8% |
| Student > Master | 1 | 8% |
| Researcher | 1 | 8% |
| Other | 2 | 17% |
| Unknown | 4 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 25% |
| Sports and Recreations | 1 | 8% |
| Computer Science | 1 | 8% |
| Unknown | 7 | 58% |
Attention Score in Context
This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 July 2018.
All research outputs
#1,732,373
of 24,884,310 outputs
Outputs from Strahlentherapie und Onkologie
#9
of 763 outputs
Outputs of similar age
#38,473
of 449,364 outputs
Outputs of similar age from Strahlentherapie und Onkologie
#2
of 7 outputs
Altmetric has tracked 24,884,310 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 763 research outputs from this source. They receive a mean Attention Score of 3.1. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 449,364 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.